POMONA, Calif., June 27, 2024 /PRNewswire/ -- Amsino Medical Group ("Amsino"), a global provider of medical consumable devices, is pleased to announce the closing of a substantial investment by Novo Tellus, a leading investment firm specialising in long-term investments in the global supply chain. Novo Tellus is deeply familiar with Amsino, having previously partnered with Amsino to create substantial growth between 2011 and 2017.
Amsino's management team and Novo Tellus aim to work closely again to grow Amsino's global production, R&D, and commitment to quality to deliver better and better solutions to customers around the world. "We're excited to renew a long-term partnership with Novo Tellus" said Dr. Richard Y.
Lee , Chairman and CEO of Amsino Medical Group, noting that "Novo Tellus has proven itself as a growth partner for Amsino before, and shares our fundamental commitment to delivering dependable innovation and value to our customers around the world." "We are already working with Novo Tellus to build Amsino into a next-generation global medical supplier. We're expanding our production facilities in the US and growing our supply chain to deliver more solutions, closer to market, for our customers.
We're proud of the long-term relationships we have with healthcare customers around the world, and we're investing in research and advanced manufacturing to bring better and better solutions to market over time," added Dr. Lee. Novo Tellus Managing Partner Loke Wai San said,.
